Plasma-derived product · developed by TAKEDA PHARMACEUTICAL CO
TAK-411 is a hypersialylated immune globulin G, a plasma-derived immunoglobulin preparation. It is being studied in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a neurological disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06798012 | Phase 2 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Recruiting | TAK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TAK catalysts and pipeline →